gsk2190915

Small moleculeexperimental

Clinical trial activity

13 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
8
Phase 3
0
Phase 4
0

Earliest trial started Dec 1, 2008 (NCT00748306)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CCOc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)cn1
Mol. weight
637.85 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 3-(3-tert-butylsulfanyl-1-(4-(6-ethoxypyridin-3-yl)benzyl)-5-(5-methylpyridin-2-ylmethoxy)-1h-indol-2-yl)-2,2-dimethylpropionic acid
  • am 803
  • am-803
  • fiboflapon
  • fiboflapon
  • fiboflapon sodium
  • fiboflapon sodium
  • gsk2190915
  • gsk2190915
  • gsk2190915
  • gsk2190915a
  • gsk2190915a
  • gsk2190915b
  • gsk2190915b
  • sodium salt

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01471665Phase 2Jun 1, 2011GlaxoSmithKline
NCT01411111Phase 1Jan 1, 2011GlaxoSmithKline
NCT01248975Phase 2Dec 1, 2010GlaxoSmithKline
NCT01286844Phase 2Nov 1, 2010GlaxoSmithKline
NCT01318980Phase 1Sep 1, 2010GlaxoSmithKline
NCT01721135Phase 1Sep 1, 2010GlaxoSmithKline
NCT01156792Phase 2Sep 1, 2010GlaxoSmithKline
NCT01147744Phase 2Jun 1, 2010GlaxoSmithKline
NCT00955383Phase 1Aug 14, 2009GlaxoSmithKline
NCT02224521Phase 1Apr 20, 2009GlaxoSmithKline
NCT00812929Phase 2Dec 1, 2008GlaxoSmithKline
NCT00812773Phase 2Dec 1, 2008GlaxoSmithKline
NCT00748306Phase 2Dec 1, 2008GlaxoSmithKline
Showing 13 of 13 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit131322008
1 organizations
Page 1 / 1